Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Sichuan Kelun-Biotech and HBM Holdings Enter Exclusive License Agreement for SKB378/HBM9378

Jan 11, 2025•over 1 year ago

Contract Type

agreement

ChengduBiotechnologyBiopharma

Description

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and HBM Holdings Limited announced an exclusive license agreement with Windward Bio AG for SKB378/HBM9378, a monoclonal antibody jointly developed by the two companies. The agreement grants Windward Bio global rights for research, development, manufacturing, and commercialization of SKB378/HBM9378, with potential payments of up to US$970 million upfront and milestone payments, as well as royalties on net sales.

Company Information

Company

Sichuan Kelun-Biotech Biopharmaceutical Ltd

Location

Chengdu, Sichuan, China

About

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in Chengdu, China, committed to developing innovative therapies for various medical conditions.

Predictive Intelligence
Strategic

ML-powered predictions for Sichuan Kelun-Biotech Biopharmaceutical Ltd's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.